173 related articles for article (PubMed ID: 20431930)
1. Biochemical alterations of the striatum in an MPTP-treated mouse model of Parkinson's disease.
Kuroiwa H; Yokoyama H; Kimoto H; Kato H; Araki T
Metab Brain Dis; 2010 Jun; 25(2):177-83. PubMed ID: 20431930
[TBL] [Abstract][Full Text] [Related]
2. Role of reactive nitrogen and reactive oxygen species against MPTP neurotoxicity in mice.
Yokoyama H; Takagi S; Watanabe Y; Kato H; Araki T
J Neural Transm (Vienna); 2008 Jun; 115(6):831-42. PubMed ID: 18235988
[TBL] [Abstract][Full Text] [Related]
3. Failure of acute administration with proteasome inhibitor to provide a model of Parkinson's disease in mice.
Kadoguchi N; Kimoto H; Yano R; Kato H; Araki T
Metab Brain Dis; 2008 Jun; 23(2):147-54. PubMed ID: 18425568
[TBL] [Abstract][Full Text] [Related]
4. Riluzole (2-amino-6-trifluoromethoxy benzothiazole) attenuates MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
Araki T; Muramatsu Y; Tanaka K; Matsubara M; Imai Y
Neurosci Lett; 2001 Oct; 312(1):50-4. PubMed ID: 11578843
[TBL] [Abstract][Full Text] [Related]
5. A novel anti-Parkinsonian agent, zonisamide, attenuates MPTP-induced neurotoxicity in mice.
Yano R; Yokoyama H; Kuroiwa H; Kato H; Araki T
J Mol Neurosci; 2009 Sep; 39(1-2):211-9. PubMed ID: 19199078
[TBL] [Abstract][Full Text] [Related]
6. Gender differences on MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in C57BL/6 mice.
Ookubo M; Yokoyama H; Kato H; Araki T
Mol Cell Endocrinol; 2009 Nov; 311(1-2):62-8. PubMed ID: 19631714
[TBL] [Abstract][Full Text] [Related]
7. Biochemical, behavioral and immunohistochemical alterations in MPTP-treated mouse model of Parkinson's disease.
Kurosaki R; Muramatsu Y; Kato H; Araki T
Pharmacol Biochem Behav; 2004 May; 78(1):143-53. PubMed ID: 15159144
[TBL] [Abstract][Full Text] [Related]
8. MPTP neurotoxicity is highly concordant between the sexes among BXD recombinant inbred mouse strains.
Alam G; Miller DB; O'Callaghan JP; Lu L; Williams RW; Jones BC
Neurotoxicology; 2016 Jul; 55():40-47. PubMed ID: 27182044
[TBL] [Abstract][Full Text] [Related]
9. Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration.
Muthian G; Mackey V; King J; Charlton CG
Neuroscience; 2010 Sep; 169(3):1085-93. PubMed ID: 20540993
[TBL] [Abstract][Full Text] [Related]
10. Evidence for a dissociation between MPTP toxicity and tyrosinase activity based on congenic mouse strain susceptibility.
Hofele K; Sedelis M; Auburger GW; Morgan S; Huston JP; Schwarting RK
Exp Neurol; 2001 Mar; 168(1):116-22. PubMed ID: 11170726
[TBL] [Abstract][Full Text] [Related]
11. Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice.
Kurosaki R; Muramatsu Y; Kato H; Watanabe Y; Imai Y; Itoyama Y; Araki T
Eur Neuropsychopharmacol; 2005 Jan; 15(1):57-67. PubMed ID: 15572274
[TBL] [Abstract][Full Text] [Related]
12. Protective action of neuronal nitric oxide synthase inhibitor in the MPTP mouse model of Parkinson's disease.
Watanabe Y; Kato H; Araki T
Metab Brain Dis; 2008 Mar; 23(1):51-69. PubMed ID: 18030609
[TBL] [Abstract][Full Text] [Related]
13. Protection of dopaminergic neurons with a novel astrocyte modulating agent (R)-(-)-2-propyloctanoic acid (ONO-2506) in an MPTP-mouse model of Parkinson's disease.
Kato H; Araki T; Imai Y; Takahashi A; Itoyama Y
J Neurol Sci; 2003 Apr; 208(1-2):9-15. PubMed ID: 12639719
[TBL] [Abstract][Full Text] [Related]
14. Dehydroepiandrosterone (DHEA) such as 17beta-estradiol prevents MPTP-induced dopamine depletion in mice.
D'Astous M; Morissette M; Tanguay B; Callier S; Di Paolo T
Synapse; 2003 Jan; 47(1):10-4. PubMed ID: 12422368
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective effect of riluzole in MPTP-treated mice.
Araki T; Kumagai T; Tanaka K; Matsubara M; Kato H; Itoyama Y; Imai Y
Brain Res; 2001 Nov; 918(1-2):176-81. PubMed ID: 11684056
[TBL] [Abstract][Full Text] [Related]
16. Substantial telomere shortening in the substantia nigra of telomerase-deficient mice does not increase susceptibility to MPTP-induced dopamine depletion.
Oeckl P; Scheffold A; Lechel A; Rudolph KL; Ferger B
Neuroreport; 2014 Mar; 25(5):335-9. PubMed ID: 24525820
[TBL] [Abstract][Full Text] [Related]
17. Rifampicin attenuates the MPTP-induced neurotoxicity in mouse brain.
Oida Y; Kitaichi K; Nakayama H; Ito Y; Fujimoto Y; Shimazawa M; Nagai H; Hara H
Brain Res; 2006 Apr; 1082(1):196-204. PubMed ID: 16515773
[TBL] [Abstract][Full Text] [Related]
18. Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice.
Leng A; Mura A; Hengerer B; Feldon J; Ferger B
Behav Brain Res; 2004 Oct; 154(2):375-83. PubMed ID: 15313025
[TBL] [Abstract][Full Text] [Related]
19. Behavioral, Biochemical and Molecular Characterization of a Parkinson's Disease Mouse Model Using the Neurotoxin 2'-CH
Herlinger AL; Almeida AR; Presti-Silva SM; Pereira EV; Andrich F; Pires RGW; Martins-Silva C
Neuromolecular Med; 2018 Mar; 20(1):73-82. PubMed ID: 29332269
[TBL] [Abstract][Full Text] [Related]
20. Expression of S-100 protein is related to neuronal damage in MPTP-treated mice.
Muramatsu Y; Kurosaki R; Watanabe H; Michimata M; Matsubara M; Imai Y; Araki T
Glia; 2003 May; 42(3):307-13. PubMed ID: 12673835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
